Edition:
United Kingdom

Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

20.42USD
4:35pm GMT
Change (% chg)

$0.97 (+4.99%)
Prev Close
$19.45
Open
$19.48
Day's High
$20.53
Day's Low
$19.40
Volume
62,687
Avg. Vol
147,499
52-wk High
$25.04
52-wk Low
$12.36

Latest Key Developments (Source: Significant Developments)

Abcellera And Denali Therapeutics Sign Expanded Multi-Year, Multi-Target
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - AbCellera::ABCELLERA AND DENALI THERAPEUTICS SIGN EXPANDED MULTI-YEAR, MULTI-TARGET DEAL TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL DISEASES.ABCELLERA SAYS WILL RECEIVE A TECHNOLOGY ACCESS FEE AND RESEARCH FUNDING.ABCELLERA SAYS IS ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES BASED ON DEVELOPMENT AND COMMERCIALIZATION OF ANTIBODIES.  Full Article

Sirion Biotech & Denali Therapeutics Join Forces To Develop Gene Therapies For Diseases Of Central Nervous System
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - :SIRION BIOTECH AND DENALI THERAPEUTICS JOIN FORCES TO DEVELOP GENE THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM.SIRION - TERMS OF AGREEMENT INCLUDE DEVELOPMENT EXPENSES, UPFRONT, CONTINGENT MILESTONE PAYMENTS TO CO, LOW-TO-MID SINGLE DIGIT ROYALTIES ON NET SALES .  Full Article

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS WITH ITS LEAD RIPK1 INHIBITOR MOLECULE AND INTENTION TO INITIATE PATIENT STUDIES IN MULTIPLE INDICATIONS IN COLLABORATION WITH SANOFI.DENALI THERAPEUTICS INC - DENALI AND PARTNER SANOFI PLAN TO EVALUATE DNL747 IN CLINICAL STUDIES FOR ALZHEIMER'S DISEASE.DENALI THERAPEUTICS INC - DENALI AND PARTNER SANOFI PLAN TO EVALUATE DNL747 IN CLINICAL STUDIES FOR ALS AND MULTIPLE SCLEROSIS (MS).DENALI THERAPEUTICS INC - PHASE 1 HEALTHY VOLUNTEER STUDY OF DNL747 MEETS ALL ENDPOINTS.DENALI THERAPEUTICS INC - IN ADDITION TO DNL747, SANOFI AND DENALI ARE PURSUING SEVERAL OTHER COMPOUNDS, INCLUDING DNL758.DENALI THERAPEUTICS INC - SANOFI INTENDS TO INITIATE CLINICAL TRIALS WITH DNL758 IN 2019..  Full Article

Denali Therapeutics Inc Reports Q3 Loss Per Share Of $0.38
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS AND ANNOUNCES THE APPOINTMENT OF JENNIFER COOK TO BOARD OF DIRECTORS.DENALI THERAPEUTICS INC QTRLY COLLABORATION REVENUE WAS $1.2 MILLION.DENALI THERAPEUTICS INC QTRLY LOSS PER SHARE $0.38.  Full Article

Denali & Sanofi To Jointly Develop RIPK1 Inhibitors
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES BROAD COLLABORATION WITH SANOFI TO DEVELOP RIPK1 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND INFLAMMATORY DISEASES.TO RECEIVE $125 MILLION UPFRONT PAYMENT AND FUTURE MILESTONE PAYMENTS THAT COULD EXCEED $1 BILLION.DENALI - PLAN TO JOINTLY DEVELOP,COMMERCIALIZE PROGRAMS FOR NEUROLOGICAL INDICATIONS;SANOFI WILL DO THE SAME FOR SYSTEMIC INFLAMMATORY INDICATIONS.TWO LEAD MOLECULES DNL747 AND DNL758 TARGET A CRITICAL SIGNALING IN TNF RECEPTOR PATHWAY.DENALI - WILL SHARE PROFITS FROM DNL747 IN U.S., CHINA EQUALLY;WILL RECEIVE ROYALTY FROM SANOFI FOR OTHER TERRITORIES FOR DNL747, WORLDWIDE FOR DNL758.PHASE 3 TRIALS FOR ALL NEUROLOGICAL INDICATIONS WILL BE JOINTLY FUNDED BY SANOFI (70%) AND DENALI (30%).SANOFI WILL FULLY FUND CLINICAL DEVELOPMENT COSTS FOR DNL758 IN SYSTEMIC INFLAMMATORY DISEASES..  Full Article

Denali Therapeutics Inc - QTRLY Loss Per Share $0.59
Thursday, 9 Aug 2018 

Denali Therapeutics Inc ::DENALI THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.DENALI THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.59.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $1.6 MILLION FOR THREE MONTHS ENDED JUNE 30, 2018, WITH NO COLLABORATION REVENUE RECOGNIZED YEAR AGO QUARTER.  Full Article

Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program For Parkinson'S Disease
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM LRRK2 INHIBITOR PROGRAM FOR PARKINSON’S DISEASE.DENALI THERAPEUTICS INC - DNL201 WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IN STUDY.DENALI THERAPEUTICS INC - DNL201 WILL ADVANCE TO PHASE 1B IN PARKINSON'S DISEASE PATIENTS WITH AND WITHOUT A GENETIC LRRK2 MUTATION.DENALI THERAPEUTICS INC - HEALTHY VOLUNTEER STUDY OF DNL201 MEETS ALL OBJECTIVES IN PHASE 1 CLINICAL STUDY.  Full Article

Denali Therapeutics Announces Early Exercise Of Its Option To Acquire F-Star Gamma
Wednesday, 30 May 2018 

May 30 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS ANNOUNCES EARLY EXERCISE OF ITS OPTION TO ACQUIRE F-STAR GAMMA.DENALI - CONSIDERATION FOR OPTION EXERCISE AND EXPANDED COLLABORATION AMOUNTS TO $24 MILLION, PLUS ANY NET CASH HELD BY F-STAR GAMMA.DENALI THERAPEUTICS INC - DENALI MAY MAKE FUTURE CONTINGENT PAYMENTS UP TO MAXIMUM OF $447 MILLION UPON ACHIEVEMENT OF MILESTONES.  Full Article

Denali Therapeutics Reports Q1 Loss Of $0.26 Per Share
Friday, 11 May 2018 

May 11 (Reuters) - Denali Therapeutics Inc ::DENALI THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.DENALI THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.26.  Full Article

Takeda And Denali Therapeutics Collaborate To Develop Therapies For Neurodegenerative Diseases
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA AND DENALI THERAPEUTICS COLLABORATE TO DEVELOP AND COMMERCIALIZE THERAPIES FOR NEURODEGENERATIVE DISEASES.DENALI THERAPEUTICS - TAKEDA TO MAKE AN INITIAL PAYMENT TO CO OF $150 MILLION THROUGH COMBINATION OF CASH UPFRONT PAYMENTS AND PURCHASE OF DENALI EQUITY.DENALI THERAPEUTICS - TO BE RESPONSIBLE FOR DEVELOPMENT ACTIVITIES AND COSTS PRIOR TO IND FILING FOR EACH OF THREE PROGRAMS.DENALI - WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS, INCLUDING $90 MILLION IN PRECLINICAL MILESTONES & OPT-IN PAYMENTS.DENALI THERAPEUTICS - COLLABORATION AGREEMENT TO DEVELOP,COMMERCIALIZE UP TO 3 SPECIFIED THERAPEUTIC PRODUCT CANDIDATES FOR NEURODEGENERATIVE DISEASES.DENALI - TAKEDA, CO WILL JOINTLY COMMERCIALIZE PRODUCTS IN U.S., CHINA, TAKEDA WILL HAVE EXCLUSIVE COMMERCIALIZATION RIGHTS IN ALL OTHER MARKETS.DENALI THERAPEUTICS - TAKEDA, CO WILL SHARE GLOBAL PROFITS FROM COLLABORATION EQUALLY.DENALI THERAPEUTICS INC - TAKEDA HAS OPTION TO CO-DEVELOP AND CO-COMMERCIALIZE EACH OF THREE PROGRAMS.  Full Article